Embattled Defense Secretary Pete Hegseth faces intense congressional scrutiny over a series of controversies, including a Signal leak and high-profile Pentagon spending.
Insmed's stock surges 27% after positive Phase 2b trial results for its pulmonary hypertension treatment, positioning it as a potential breakthrough therapy.
Embattled Defense Secretary Pete Hegseth faces intense congressional scrutiny over a series of controversies, including a Signal leak and high-profile Pentagon spending.
Insmed's stock surges 27% after positive Phase 2b trial results for its pulmonary hypertension treatment, positioning it as a potential breakthrough therapy.